Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian D Lehmann

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
New strategies for triple-negative breast cancer--deciphering the heterogeneityIngrid A Mayer, Vandana G Abramson, Brian D Lehmann, et al.
Cancer|July 22, 2014
Subtyping of triple-negative breast cancer: implications for therapyVandana G Abramson, Brian D Lehmann, Tarah J Ballinger, et al.
Genes|January 11, 2018
The Landscape of Small Non-Coding RNAs in Triple-Negative Breast CancerYan Guo, Hui Yu, Jing Wang, et al.
Genomics|July 24, 2017
Estimating relative mitochondrial DNA copy number using high throughput sequencing dataPan Zhang, Brian D Lehmann, David C Samuels, et al.
Cell Cycle (Georgetown, Tex.)|April 18, 2008
Distinct roles for p107 and p130 in Rb-independent cellular senescenceBrian D Lehmann, Adam M Brooks, Matthew S Paine, et al.
Oncotarget|September 2, 2011
Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cellsJackson R Taylor, Brian D Lehmann, William H Chappell, et al.
Cell Cycle (Georgetown, Tex.)|March 14, 2007
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cellsBrian D Lehmann, James A McCubrey, Holly S Jefferson, et al.
Cell Cycle (Georgetown, Tex.)|November 29, 2012
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3William H Chappell, Brian D Lehmann, David M Terrian, et al.
Cancer Informatics|August 9, 2012
TNBCtype: A Subtyping Tool for Triple-Negative Breast CancerXi Chen, Jiang Li, William H Gray, et al.
The Journal of Clinical Investigation|June 3, 2011
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesBrian D Lehmann, Joshua A Bauer, Xi Chen, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
New strategies for triple-negative breast cancer--deciphering the heterogeneityIngrid A Mayer, Vandana G Abramson, Brian D Lehmann, et al.
Cancer|July 22, 2014
Subtyping of triple-negative breast cancer: implications for therapyVandana G Abramson, Brian D Lehmann, Tarah J Ballinger, et al.
Genes|January 11, 2018
The Landscape of Small Non-Coding RNAs in Triple-Negative Breast CancerYan Guo, Hui Yu, Jing Wang, et al.
Genomics|July 24, 2017
Estimating relative mitochondrial DNA copy number using high throughput sequencing dataPan Zhang, Brian D Lehmann, David C Samuels, et al.
Cell Cycle (Georgetown, Tex.)|April 18, 2008
Distinct roles for p107 and p130 in Rb-independent cellular senescenceBrian D Lehmann, Adam M Brooks, Matthew S Paine, et al.
Oncotarget|September 2, 2011
Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cellsJackson R Taylor, Brian D Lehmann, William H Chappell, et al.
Cell Cycle (Georgetown, Tex.)|March 14, 2007
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cellsBrian D Lehmann, James A McCubrey, Holly S Jefferson, et al.
Cell Cycle (Georgetown, Tex.)|November 29, 2012
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3William H Chappell, Brian D Lehmann, David M Terrian, et al.
Cancer Informatics|August 9, 2012
TNBCtype: A Subtyping Tool for Triple-Negative Breast CancerXi Chen, Jiang Li, William H Gray, et al.
The Journal of Clinical Investigation|June 3, 2011
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesBrian D Lehmann, Joshua A Bauer, Xi Chen, et al.
Pageof 7